Douglas Ward
Director Ejecutivo en LUMOS DIAGNOSTICS HOLDINGS LIMITED .
Fortuna: 11 690 $ al 31/05/2024
Cargos activos de Douglas Ward
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| LUMOS DIAGNOSTICS HOLDINGS LIMITED | Director/Miembro de la Junta | 13/07/2023 | - |
| Director Ejecutivo | 21/06/2022 | - |
Historial de carrera de Douglas Ward
Antiguos cargos conocidos de Douglas Ward.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
Personal Genome Diagnostics, Inc.
 Personal Genome Diagnostics, Inc. BiotechnologyHealth Technology Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD. | Director Ejecutivo | 09/05/2016 | 21/04/2020 |
| HOLOGIC, INC. | Corporate Officer/Principal | - | - |
Formación de Douglas Ward.
| Ohio Wesleyan University | Undergraduate Degree |
Estadísticas
Internacional
| Estados Unidos | 4 |
| Australia | 2 |
Operativa
| Chief Executive Officer | 2 |
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Sectorial
| Health Technology | 4 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| LUMOS DIAGNOSTICS HOLDINGS LIMITED | Health Technology |
| HOLOGIC, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Personal Genome Diagnostics, Inc.
Personal Genome Diagnostics, Inc. BiotechnologyHealth Technology Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD. | Health Technology |
- Bolsa de valores
- Insiders
- Douglas Ward
- Experiencia
